Candel Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CADL research report →
Range $22 – $23
Price Chart
About the company
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer.
- CEO
- Paul-Peter Tak
- IPO
- 2021
- Employees
- 55
- HQ
- Needham, MA, US
Get TickerSpark's AI analysis on CADL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $904.89M
- P/E
- -8.76
- Fwd P/E
- 24.36
- PEG
- 0.11
- P/S
- 0.00
- P/B
- 7.26
- EV/EBITDA
- -9.06
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -89.38%
- ROIC
- -36.74%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-48,266,000
- Net Income
- $-38,182,000+30.8%
- EPS
- $-0.72+58.6%
- OCF Growth
- -41.8%
- FCF Growth
- -43.9%
- 52W High
- $13.82
- 52W Low
- $4.35
- 50D MA
- $9.90
- 200D MA
- $6.91
- Beta
- -0.50
- RSI (14)
- 64
- Avg Volume
- 1.66M
No earnings-call transcripts are available for CADL yet.
- Free Float
- 77.5%
- Shares Outstanding
- 73.27M
- Float Shares
- 56.81M
of shares held by institutions
88 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.31M | ▲ 297.95K |
| Janus Henderson Group PLC | 171.98K | ▲ 171.98K |
| Quest Partners LLC | 11.94K | 0 |
| California State Teachers Retirement System | 2.37K | ▼ 327 |
| Cwm, LLC | 387 | ▲ 387 |
| Sunbelt Securities, Inc. | 16 | 0 |
Held by 117 ETFs
Biggest fund positions in CADL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Tyagarajan Seshu | sell | 7,000 |
| Jul 6, 26 | Sims Mark E. | other | 285,000 |
| Jul 6, 26 | Sims Mark E. | other | 0 |
| Jun 29, 26 | Barone Francesca | sell | 23,447 |
| Jun 29, 26 | Tyagarajan Seshu | sell | 7,000 |
| Jun 30, 26 | Manning Paul B | other | 2,199 |
| Jun 30, 26 | PAPA JOSEPH C | other | 1,331 |
| Jun 30, 26 | Loggia Nicoletta | other | 381 |
| Jun 23, 26 | Radhakrishnan Maha | other | 32,000 |
| Jun 23, 26 | Loggia Nicoletta | other | 32,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CADL coverage
Recent articles, reports, and earnings notes.
No research on CADL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CADL report →Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
seekingalpha.com · Aug 16
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Aug 13
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up
marketbeat.com · Aug 12
Candel Therapeutics: Getting Closer, And Building Out More Paths
seekingalpha.com · Aug 7
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 3
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
globenewswire.com · Aug 3
Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston
globenewswire.com · Jul 29
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.